Treace to Report Second Quarter 2025 Financial Results on August 7, 2025
Treace Medical Concepts (NASDAQ:TMCI), a medical technology company specializing in surgical treatments for bunions through its Lapiplasty® and Adductoplasty® Procedures, has scheduled its Q2 2025 earnings release for August 7, 2025 after market close.
The company will host a conference call at 4:30 PM ET to discuss the results. Investors can participate by registering to receive dial-in information. A webcast will be available on the company's investor relations website.
Treace Medical Concepts (NASDAQ:TMCI), un'azienda di tecnologia medica specializzata in trattamenti chirurgici per alluce valgo tramite le procedure Lapiplasty® e Adductoplasty®, ha programmato la pubblicazione dei risultati del secondo trimestre 2025 per il 7 agosto 2025 dopo la chiusura del mercato.
La società terrà una conference call alle 16:30 ET per discutere i risultati. Gli investitori possono partecipare registrandosi per ricevere le informazioni per la chiamata. Una webcast sarà disponibile sul sito web delle relazioni con gli investitori della società.
Treace Medical Concepts (NASDAQ:TMCI), una empresa de tecnología médica especializada en tratamientos quirúrgicos para juanetes mediante sus procedimientos Lapiplasty® y Adductoplasty®, ha programado la publicación de sus resultados del segundo trimestre de 2025 para el 7 de agosto de 2025 después del cierre del mercado.
La compañía realizará una llamada conferencia a las 4:30 PM ET para discutir los resultados. Los inversores pueden participar registrándose para recibir la información de acceso. Habrá una transmisión web disponible en el sitio web de relaciones con inversionistas de la empresa.
Treace Medical Concepts (NASDAQ:TMCI)는 Lapiplasty® 및 Adductoplasty® 시술을 통한 무지외반증 수술 치료를 전문으로 하는 의료기술 회사로, 2025년 8월 7일 장 마감 후 2025년 2분기 실적 발표를 예정하고 있습니다.
회사는 동부시간 오후 4시 30분에 실적을 논의하기 위한 컨퍼런스 콜을 개최합니다. 투자자들은 등록하여 전화 접속 정보를 받을 수 있으며, 회사 투자자 관계 웹사이트에서 웹캐스트도 제공될 예정입니다.
Treace Medical Concepts (NASDAQ:TMCI), une entreprise de technologie médicale spécialisée dans les traitements chirurgicaux des oignons grâce à ses procédures Lapiplasty® et Adductoplasty®, a programmé la publication de ses résultats du deuxième trimestre 2025 pour le 7 août 2025 après la clôture du marché.
L'entreprise organisera une conférence téléphonique à 16h30 ET pour discuter des résultats. Les investisseurs peuvent participer en s'inscrivant pour recevoir les informations d'accès. Un webcast sera disponible sur le site des relations investisseurs de la société.
Treace Medical Concepts (NASDAQ:TMCI), ein Medizintechnikunternehmen, das sich auf chirurgische Behandlungen von Hallux valgus mittels der Lapiplasty®- und Adductoplasty®-Verfahren spezialisiert hat, hat die Veröffentlichung der Ergebnisse für das zweite Quartal 2025 für den 7. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können durch Registrierung Zugangsdaten erhalten. Ein Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
PONTE VEDRA, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, August 7, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate® Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
FAQ
When will Treace Medical Concepts (TMCI) report Q2 2025 earnings?
What time is the TMCI Q2 2025 earnings conference call?
How can investors join Treace Medical's Q2 2025 earnings call?
What products does Treace Medical Concepts (TMCI) specialize in?
